MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $425,427 | +5.0% | 52,848 | +41.7% | 0.00% | – |
| Q2 2023 | $405,165 | -60.7% | 37,308 | -75.0% | 0.00% | – |
| Q1 2023 | $1,030,287 | +173.1% | 149,317 | +57.5% | 0.00% | – |
| Q4 2022 | $377,308 | +289.0% | 94,801 | +551.4% | 0.00% | – |
| Q3 2022 | $97,000 | +61.7% | 14,553 | +16.7% | 0.00% | – |
| Q2 2022 | $60,000 | -67.7% | 12,470 | -37.6% | 0.00% | – |
| Q1 2022 | $186,000 | -31.9% | 19,982 | -12.9% | 0.00% | – |
| Q4 2021 | $273,000 | +8.8% | 22,934 | +3.9% | 0.00% | – |
| Q3 2021 | $251,000 | +3.7% | 22,082 | +63.8% | 0.00% | – |
| Q2 2021 | $242,000 | -46.2% | 13,483 | -53.7% | 0.00% | – |
| Q1 2021 | $450,000 | +192.2% | 29,094 | +129.9% | 0.00% | – |
| Q4 2020 | $154,000 | +26.2% | 12,653 | +34.0% | 0.00% | – |
| Q3 2020 | $122,000 | – | 9,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |